SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Food and Drug Administration. Press release; August 24, 1994.
  • 2
    Merrill RM, Potosky AL, Feuer EJ. Changing trends in U.S. prostate cancer incidence rates. J Natl Cancer Inst. 1996; 88: 16831685.
  • 3
    Legler JM, Feuer EJ, Potosky AL, Merrill RM, Kramer BS. The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States. Cancer Causes Control. 1998; 9: 519527.
  • 4
    Hankey BF, Feuer EJ, Clegg LX, et al. Cancer surveillance series: interpreting trends in prostate cancer—part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst. 1999; 91: 10171024.
  • 5
    Feuer EJ, Merrill RM, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer—part II: cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst. 1999; 91: 10251032.
  • 6
    Etzioni R, Legler JM, Feuer EJ, Merrill RM, Cronin KA, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer—part III: quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst. 1999; 91: 10331039.
  • 7
    Tarone RE, Chu KC, Brawley OW. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology. 2000; 11: 167170.
  • 8
    Gann PH. Interpreting recent trends in prostate cancer incidence and mortality [editorial]. Epidemiology. 1997; 8: 117120.
  • 9
    Eddy DM. A computer-based model for designing cancer control strategies. Natl Cancer Inst Monogr. 1986; 2: 7582.
  • 10
    Levin DL, Gail MH, Kessler LG, Eddy DM. A model for projecting cancer incidence and mortality in the presence of prevention, screening, and treatment programs. Natl Cancer Inst Monogr. 1986; 2: 8393.
  • 11
    U.S. Department of Health Human Services Public Health Service. Healthy people 2000 (conference edition, in two volumes). Washington, DC: U.S. Department of Health and Human Services, 2000.
  • 12
    Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr. 1961; 6: 101121.
  • 13
    Pearson JD, Luderer AA, Metter EJ, et al. Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer. Urology. 1996; 48: 49.
  • 14
    Morrell CH, Pearson JD, Carter HB, Brant LJ. Estimating unknown transition times using a piecewise nonlinear mixed-effects model in men with prostate cancer. J Am Stat Assoc. 1995; 90: 4553.
  • 15
    Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 1995; 273: 289294.
  • 16
    Naser S. A beautiful mind: a biography of John Forbes Nash, Jr., winner of the Nobel Prize in economics, 1994. New York: Touchstone, 1998.
  • 17
    Merrill RM. Changes in the use of radical prostatectomy for treating prostate cancer in the USA [letter]. Lancet. 1996; 348: 963964.
  • 18
    Seidenfeld J, Samson DJ, Aronson N, et al. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Publication no. 99-E0012. Washington, DC: Agency for Health Care Policy and Research, 1999.
  • 19
    Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999; 341: 17811788.
  • 20
    Gohagan JK, Prorok PC, Kramer BS, Cornett JE. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute [see comments]. J Urol. 1994; 152: 19051909.
  • 21
    Schroder FH, Kranse R, Rietbergen J, Hoedemaeke R, Kirkels W. The European Randomized Study of Screening for Prostate Cancer (ERSPC): an update. Members of the ERSPC, Section Rotterdam. Eur Urol. 1999; 35: 539543.